mrcc patient selection for ipilimumab/nivolumab
Published 6 years ago • 726 plays • Length 7:36Download video MP4
Download video MP3
Similar videos
-
4:50
ipilimumab/nivolumab in first-line mrcc
-
2:08
nivolumab with ipilimumab for mrcc
-
3:16
optimizing the use of ipilimumab/nivolumab in mrcc
-
7:03
ipilimumab/nivolumab for favorable-risk mrcc
-
4:46
sbrt in combination with ipilimumab/nivolumab in mrcc
-
3:07
checkmate-214: nivolumab/ipilimumab for mrcc?
-
6:01
metastatic rcc: using frontline ipilimumab/nivolumab
-
6:16
treatment-free survival results of nivolumab and salvage nivolumab ipilimumab for accrcc
-
4:05
therapy selection for patients with newly diagnosed mrcc
-
0:51
dr. pal on the frontline approval of nivolumab and ipilimumab in mrcc
-
1:55
investigating responses to nivolumab and ipilimumab in advanced rcc
-
4:39
nivolumab and ipilimumab for metastatic kidney cancer
-
2:00
nivolumab and ipilimumab in mrcc
-
0:39
dr. atkinson on when to use nivolumab monotherapy versus nivolumab/ipilimumab combination
-
3:45
combination immunotherapy in newly diagnosed mrcc
-
1:30
targeted therapies for the treatment of mrcc after nivolumab-ipilimumab failure
-
4:35
patient selection for nivolumab in hnscc
-
2:52
frontline therapy options for mrcc
-
8:26
front-line therapy with nivolumab and salvage nivolumab ipilimumab in patients with advanced rcc